Search

Displaying results 2381 - 2390 of 10000 in total
  1. Target

    Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex, mitochondrial

    go.drugbank.com/bio_entities/BE0000065
    TargetHumans

    The pyruvate dehydrogenase (PDH) complex, catalyzes the overall conversion of pyruvate to acetyl-CoA and CO(2), and thereby links cytoplasmic glycolysis and the mitochondrial tricarboxylic acid (TCA) cycle … Within this complex, the catalytic function of this enzyme is to accept, and to transfer to coenzyme A, acetyl groups from acetyl-lipoyl moiety generated by the pyruvate dehydrogenase, leading to acetyl-CoA

    Polypeptides: Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex, mitochondrialSynonyms: M2 antigen complex 70 kDa subunit, Pyruvate dehydrogenase complex component E2
  2. Drug

    gamma-Aminobutyric acid

    go.drugbank.com/drugs/DB02530
    ApprovedInvestigational

    The most common inhibitory neurotransmitter in the central nervous system.

    Mixtures: Theraproxen-500, Theraprofen-800
  3. Drug

    Propyphenazone

    go.drugbank.com/drugs/DB13524
    Investigational

    Propyphenazone is a non-steroidal anti-inflammatory agent with analgesic effects.

    Mixtures: ALJIL 150 MG/300 MG/50 MG TABLET, 20 ADET, MINOSET PLUS 250 MG/150 MG/50 MG TABLET, 20 ADET
  4. Drug

    Irofulven

    go.drugbank.com/drugs/DB05786
    Investigational

    Phase III clinical trials involving the drug have been underway since early 2001 at sites in the U.S. and Europe. … MGI-114 (Irofulven) is currently being developed by MGI PHARMA, Inc., an emerging oncology-focused pharmaceutical company based in Minneapolis.

  5. Drug

    Brexanolone

    go.drugbank.com/drugs/DB11859
    ApprovedInvestigational

    brexanolone may also be undergoing clinical trials to investigate its abilities to treat super-refractory status epilepticus, it appears that some such studies have failed to meet primary endpoints that compare … As of March 2019, brexanolone - developed and made available commercially by Sage Therapeutics Inc. as the brand name product Zulresso - is the first drug to have ever been approved by the US FDA specifically

    Synonyms: allopregnan-3α-ol-20-one
  6. Drug

    Enzacamene

    go.drugbank.com/drugs/DB11219
    Approved

    Commonly known as 4-methylbenzylidene-camphor (4-MBC), enzacamene is a camphor derivative and an organic chemical UV-B filter. It is used in cosmetic products such as sunscreen to provide skin protection against UV rays. While its effect...

    Mixtures: Sebamed Sun Cream SPF 20, Sebamed Sun Lotion SPF 20
  7. Drug

    Chloride ion

    go.drugbank.com/drugs/DB14547
    Investigational

    Mixtures: POLİFLEKS LAKTATLI RİNGER IV İNFÜZYON İÇİN ÇÖZELTİ, 2000 ML (PVC TORBA) SETLI, POLİFLEKS LAKTATLI RİNGER IV İNFÜZYON İÇİN ÇÖZELTİ, 2000 ML (PVC TORBA) SETSİZ
  8. Drug

    Amrubicin

    go.drugbank.com/drugs/DB06263
    Investigational

    Pharmion licensed the rights to Amrubicin in November 2006. In 2002, Amrubicin was approved and launched for sale in Japan based on Phase 2 efficacy data in both SCLC and NSCLC. … Since January 2005, Amrubicin has been marketed by Nippon Kayaku, a Japanese pharmaceutical firm focused on oncology, which licensed Japanese marketing rights from Dainippon Sumitomo, the original developer

  9. Drug

    Sodium citrate

    go.drugbank.com/drugs/DB09154
    ApprovedInvestigational

    Sodium citrate is the sodium salt of citric acid. It is white, crystalline powder or white, granular crystals, slightly deliquescent in moist air, freely soluble in water, practically insoluble in alcohol. Like citric acid, it has a sour...

    Mixtures: SODIO60 MCG +POTASIO 20 MCG + CLORURO 50 MCG + CITRATO 30 MG + GLUCOSA111 MCG, LITORAL TOZ, 20 ADETProducts: Urobase Sachet 4g for Oral Solution
  10. Drug

    Tegaserod

    go.drugbank.com/drugs/DB01079
    ApprovedWithdrawn

    Novartis' brand name Zelnorm (tegaserod) had originally received approval from the US FDA in 2002 for the treatment of irritable bowel syndrome with constipation (IBS-C). … [L5918,F4229] It was, however, voluntarily withdrawn from widespread use in the US market in 2007 after concerns arose over the possibility that tegaserod could potentially cause dangerous cardiovascular